Banjin Likang Powder Veterinary Grade API is supplied as a non-sterile powder intended for conversion into finished veterinary dosage forms. The material is routinely released against a certificate of analysis covering appearance, identification, assay on dried basis, loss on drying at 105°C, related substances by HPLC, and particle-size distribution by laser diffraction according to ISO 13320:2020. For tablet manufacture, the API is pre-blended with lactose monohydrate and microcrystalline cellulose in a high-shear granulator at an impeller speed of 200–400 rpm for 3–5 min. Blend uniformity is assessed by sampling 10 positions after blending; acceptance is 90–110% of target with a relative standard deviation of ≤5.0% according to current FDA guidance for powder blends. Content uniformity of compressed tablets is confirmed by USP <905>, and weight uniformity is assessed by EP 2.9.5. Magnesium stearate is added at 0.25–1.0% w/w and mixed for 3–5 min; overlubrication is identified by a drop in tablet breaking force below 70 N when tested according to USP <1217>. Compression is performed on a rotary tablet press with a turret speed of 30–80 rpm, precompression force of 3–8 kN, and main compression force of 10–25 kN. Compressed tablets are sampled for friability per USP <1216> with an acceptance limit of ≤1.0%, and disintegration per USP <701> with a limit of ≤15 min in water at 37°C. Dissolution testing is conducted using USP <711> Apparatus II at 50 rpm in 0.1 M hydrochloric acid; the Q value is set from the veterinary product dossier and is commonly ≥80% released at 30 min. The finished tablet is a scored oral solid intended for companion-animal or equine dosing, packaged in PVC/aluminium blisters and labelled with the withdrawal period required under EU Regulation 2019/6 or the applicable national registration. Batch records include loss on drying at 105°C with release specification of ≤2.0% if the API is moisture-sensitive, and a tablet hardness range of 70–120 N for immediate-release formulations. Dry granulation is preferred over wet granulation when the API undergoes hydrolysis at moisture contents above 3.0%; a roller compactor with hydraulic pressure of 30–60 bar and a milling screen of 0.8 mm is used to produce granules with a bulk density of 0.55–0.75 g/cm³.

Injectable Preparation Limits and Particulate Control

In terminal sterilisation of injectable solutions, the API is dissolved in Water for Injection under aseptic conditions and the bulk solution is filtered through a 0.22 µm polyethersulfone membrane. Bioburden monitoring before sterilisation is performed according to USP <61> and USP <62>, with an alert limit of ≤10 CFU/100 mL. The filled vials are sterilised by moist heat at 121°C for 15 min; if the API is thermolabile, a lower terminal cycle of 115°C for 30 min is justified by a sterility assurance level of 10⁻⁶ under USP <1229>. Sterility of the finished vial is confirmed by direct inoculation per USP <71>, and bacterial endotoxin is tested by kinetic chromogenic assay per USP <85>; the limit is calculated from maximum label dose and body weight and expressed as EU/kg. Particulate contamination is measured by light obscuration per USP <788>; for small-volume parenterals the acceptance is ≤6,000 particles ≥10 µm and ≤600 particles ≥25 µm per container. If the injectable is presented as a multi-dose vial, antimicrobial effectiveness testing per USP <51> applies, with bacterial reduction of 1.0 log at 7 days and 3.0 log at 14 days for compendial challenge organisms. Lyophilised injections are processed at a primary drying shelf temperature of -25°C to -10°C and chamber pressure of 0.2–0.5 mbar; collapse temperature is determined by freeze-drying microscopy before cycle scale-up. Stopper closure integrity is assessed by dye ingress per USP <1207> and vacuum decay per USP <1207.2>. Process conflicts include pH drift during autoclaving; citrate or phosphate buffers at 5–20 mM are used when pH shift exceeds 0.2 units. Compatibility with siliconised stoppers is evaluated over 48 h at 25°C because silicone oil droplets above 0.1 µL/mL can increase subvisible particle counts under USP <788>. The terminal product is a sterile injectable solution or lyophilised plug in Type I glass vials of 10 mL, 20 mL, or 50 mL.

When the API is filled into hard gelatin capsules for companion-animal and equine oral therapy, powder flow and density are controlled by pre-compaction or dry granulation because capsule weight variation worsens when Carr index exceeds 25%. The blend is prepared in a bin blender with a fill volume of 50–70% and rotation speed of 8–15 rpm. Colloidal silicon dioxide is added at 0.2–1.0% w/w to improve flow, and sodium stearyl fumarate at 0.5–1.5% w/w is used instead of magnesium stearate when the API is sensitive to alkaline lubrication. Encapsulation is performed on a dosator-type capsule filling machine operating at 30,000–60,000 capsules/h; capsule weight variation must comply with EP 2.9.5, and content uniformity is confirmed by USP <905>. Dissolution is tested in USP <711> Apparatus I at 100 rpm with 0.01 M hydrochloric acid, with an acceptance criterion of ≥75% released at 45 min unless the veterinary dossier specifies otherwise. The filled capsule shell is gelatin or hydroxypropyl methylcellulose; HPMC shells are selected when the fill material moisture content exceeds 3.0% because gelatin cross-linking under accelerated storage can retard release by 10–20%. Powder plug formation on the dosator is controlled by pin settings of 2–5 mm below fill level. A stability-indicating assay is performed after 1 month at 40°C/75% RH; degradation products are quantified by HPLC and reported according to VICH GL18, with an identification threshold of 0.2% and a qualification threshold of 0.5% for unknown impurities in the API. Terminal capsules are size 0 or size 1, printed with the veterinary prescription legend, and packaged in HDPE bottles with desiccant if moisture uptake exceeds 2.0%.

What Governs Oral Powder Dispersion in Swine Drinking Water Lines?

Dispersion of the API as an oral water-soluble powder for mass medication depends on particle-size distribution, carrier solubility, and hard-water pH. The material is blended with anhydrous glucose or sodium citrate as a water-soluble carrier to reduce hydrophobic surface agglomeration; the carrier is milled to a D90 below 300 µm before blending. Dry blend uniformity is sampled at 10 locations and assayed; acceptance is 90–110% of the label claim with a relative standard deviation of ≤5.0% under EU Regulation 2019/6. Stock solutions are prepared at 0.1–1.0 g/L depending on the labelled dose; if alkalinity exceeds 200 mg/L CaCO₃, citric acid is incorporated at 0.1–0.5% w/w to maintain solubility. The powder is dispersed through a proportioner pump with an in-line 63 µm screen; clogging is monitored by pressure drop across the screen, with a cumulative pressure increase of 0.2 bar triggering cleaning. Water medication runs are limited to 4–24 h depending on species and barn conditions; leftover medicated water is discarded according to the label. Sedimentation is measured in a 1 L cylinder at 25°C; after 30 min, sediment volume must not exceed 5 mL. The finished oral powder is packaged in 10 kg or 25 kg foil-lined pouches with a measuring scoop calibrated for 500 L or 1,000 L stock tanks. Terminal product labeling includes the withdrawal period for swine, maximum mass per 1,000 L, and a statement that the preparation is for oral administration only under veterinary prescription. Stability after reconstitution is tested at 5°C and 25°C for 24 h; if potency falls below 90% of initial, the product is restricted to 4 h stock solution use. Equipment residues are verified by swab testing with an acceptance limit not exceeding 0.1 µg/cm².

After dry blending, fluid-bed granulation of the API with a povidone binder at 3–5% w/w produces free-flowing granules for oral dosing or sachet presentation. The granulator operates with inlet air temperature of 55–70°C, product temperature of 30–40°C, spray rate of 10–30 g/min for a 5 kg batch, and atomising air pressure of 1.0–2.0 bar. Granules are dried to a loss on drying of 1.0–3.0% and passed through a 1.0 mm oscillating sieve. Particle-size distribution is measured according to EP 2.9.38, with acceptance of ≥80% between 150 µm and 850 µm. Content uniformity after granulation is verified by USP <905>, and residual moisture is controlled because granule flow worsens at moisture contents above 3.0%. The granulation process is preferred when direct compression produces unacceptable segregation; a segregation index is calculated by comparing assay variance at the top, middle, and bottom of a hopper after 10 min of vibration. If the spray rate exceeds 30 g/min while product temperature drops below 25°C, uncontrolled agglomeration and filter bag blockage occur. The finished granules are filled into 1 g or 5 g sachets and sealed against moisture; seal integrity is tested by vacuum decay and visual inspection with acceptance of no leak at -50 kPa for 30 s. For feed incorporation, granules are dry-dispersed into meal or pellet feed; content uniformity of medicated feed is then tested by EU Regulation 2019/6 sampling of 10 points. Cleaning validation after granulation uses rinse water testing by HPLC, and the acceptance limit is ≤10 µg/mL in final rinse water.

When Premix Carriers Fail Homogeneity Testing

If ribbon-blender mixing at the 1:100 dilution stage shows an individual potency outside 90–110%, a medicated premix is corrected by adjusting the carrier grade and re-screening through a 500 µm screen. A carrier system based on lactose or ground corncob with a tapped bulk density of 0.45–0.70 g/cm³ is used for stepwise dilution of the API. The first preblend is made at a ratio of 1:10, followed by serial dilution to 1:100 and 1:1,000. Mixing is performed in a ribbon blender with a fill level of 60–70% and a shaft speed of 20–40 rpm; homogeneity is assessed at 3 time points using 10 sampling probes. Acceptance is individual potency 90–110% of the claim and relative standard deviation ≤5.0% under EU Regulation 2019/6 and 21 CFR 225.142. Carriers with an angle of repose greater than 40° show segregation during bin transfer; electrostatic charges on polyethylene bin surfaces reduce API recovery by 2–5% at relative humidity below 35%. The terminal premix is incorporated into finished feed at 2–10 kg/tonne at the feed mill. Mineral oil is added at 0.5–1.0% to suppress dusting; overdose beyond 1.5% reduces pellet durability index below 95% when the feed is steam-conditioned and pelleted at 75–85°C. Cleaning validation is performed after each batch because residual API in mixer dead zones can cause cross-contamination above 0.1% of maximum daily intake. The premix label includes the species, inclusion rate, maximum treatment duration, and withdrawal period; medicated feed production must comply with 21 CFR 225 or the relevant national feed additive regulation. If the initial homogeneity test fails, the batch is re-mixed in increments of 2 min and retested; repeated failures are traced to carrier moisture above 10% or overloaded blender volume above 80%.

Assessing Buffering Capacity in Oral Solution Formulations

For proportioner-pump dosing systems in poultry houses, oral solutions prepared from the API are concentrated, clear liquids dispensed at 1–5% dilution into drinking water. Solubilisation is achieved by pH adjustment with citric acid or phosphoric acid; if the API has pH-dependent solubility, the pH is maintained at 3.0–5.0 for acid salt forms. The solution is filtered through a 10 µm in-line bag filter before bottling; clarity and opalescence are assessed visually per EP 2.2.1 with a limit of not more than 10 NTU. Preservative efficacy for multi-dose oral containers is evaluated using USP <51>; sorbic acid at 0.15–0.30% w/v is added when microbial challenge testing demonstrates insufficient log reduction. The terminal product may be a 1 L or 5 L opaque high-density polyethylene bottle with a dosing chamber. Stability after dilution in drinking water is tested at 25°C and 5°C; degradation products are below the identification threshold per VICH GL18. A cloud point is measured when non-ionic surfactants are used; for polysorbate 80 at 0.1% w/v, a cloud point above 70°C is required to avoid phase separation in tropical storage. The solution must remain free of crystal formation after 3 freeze-thaw cycles from -10°C to 25°C. Cleaning of proportioner equipment uses a potable water rinse followed by a validated alkaline detergent; final rinse water is tested for conductivity below 10 µS/cm and for API residue below the limit of quantification. Batch records include pH, density, refractive index, and assay by HPLC; the finished product is labelled with an expiration date supported by stability data at 30°C/65% RH for 24 months. Because hard-water cations above 200 mg/L CaCO₃ can form insoluble salts with some APIs, a water-hardness compatibility statement is included on the label when the formulation is intended for use in multiple geographic regions.